Sign up
Pharma Capital

Physiomics Plc RNS Release

Physiomics participates at NIHR event


RNS Number : 0568Y
Physiomics PLC
03 May 2019
 

 

3rd May 2019

Physiomics plc

("Physiomics") or ("the Company")

 

 

Physiomics participates at NIHR event

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, yesterday participated in the "SME Dragon's Den" event jointly organised by the National Institute for Health Research ("NIHR") Biomedical Research Centre at The Royal Marsden NHS Foundation Trust, the Institute of Cancer Research and DigitalHealth London Accelerator.

 

Dr Claire Villette and Dr Jim Millen presented for 5 minutes and were then grilled by a panel of over 15 UK-based experts in the field of oncology as well as by patient representatives.  The presentation was well-received and the questioning lively and informative.  There were no formal "winners" at this event and the prize was not cash but rather contact and engagement with some of the country's leading oncology clinicians and researchers.  Physiomics will follow up with key participants with a view to garnering feedback, forming partnerships and accessing further data for the purposes of developing and validating its personalised oncology tools.

 

 

 

Enquiries:

 

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

WH Ireland Limited (NOMAD)

Katy Mitchell

James Sinclair-Ford

+44 (0) 161 832 2174

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Notes to Editor

 

This is an RNS Reach

 

About Physiomics

 

Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.

 

Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.

 

Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAUOVRRKOAVRAR



© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.